Clinically validated SmartHealth AI Stations anchor expansion into Clinical-Trial Optimization and Consumer Digital Health, creating multiple recurring-revenue opportunities

Predictmedix AI Inc, an emerging leader in AI-powered health and safety technology, outlined a strategic plan to evolve from a single-product health-screening company into a diversified, AI-driven health-technology enterprise with three complementary growth platforms.

Health Technology Insights: Agiliti Expands Prostate Cancer Care Solutions

Clinically validated SmartHealth AI Stations anchor expansion into Clinical-Trial Optimization and Consumer Digital Health, creating multiple recurring-revenue opportunities.

Three Growth Platforms

Clinical-Trial AI Platform – Primary Near-Term Driver

Predictmedix is developing an adaptive-AI engine designed to simulate, optimize, and predict outcomes across multi-site clinical trials—addressing a global clinical trials market projected to reach USD $123.5 billion by 2030, growing at a CAGR of ~6.5 % from 2024 to 20301.

The SaaS-based platform is intended to provide trial simulation, cross-trial learning, cost/outcome modeling, and full regulatory traceability.

Health Technology Insights: LogicMark Launches Predictive Activity Metrics in Freedom Alert Max Device

SmartHealth AI Stations – Global Commercialization

The Company’s contactless, screening systems have demonstrated approximately 95% accuracy in detecting impairment, infectious disease, and multiple vital signs, supported by independent, multi-center clinical validation. Predictmedix is assessing regulatory requirements in multiple jurisdictions, including Southeast Asia, and plans to initiate formal medical-device certification processes as a next step toward global deployment for enterprise health & safety, hospital triage, and government health programs.

Consumer Vital-Scanning Mobile Application – Direct-to-Consumer Entry

A planned mobile application will leverage Predictmedix’s patented imaging technology to deliver vital-sign monitoring through a smartphone, extending the Company’s platform into the growing digital-health and telehealth markets.

Strategic Rationale

  • Recurring revenue potential: SaaS subscriptions for the Clinical-Trial AI platform; Screening-as-a-Service for enterprises and hospitals; consumer subscriptions for the mobile app.
  • Defensible IP: Proprietary adaptive-simulation engine and patented multispectral imaging algorithms.
  • Large addressable markets: The global AI in healthcare market was estimated at USD $26.6 billion in 2024 and is projected to reach approximately USD $187.7 billion by 2030, growing at a ~38.6 % CAGR from 2025-2030.2

“Our validated SmartHealth technology provides the data, AI engine, and market credibility to scale across enterprise, clinical-research, and consumer segments,” said Dr. Rahul Kushwah, Chief Operating Officer of Predictmedix. “This multi-vertical approach is designed to diversify revenue and support sustainable long-term growth for our shareholders.”

Health Technology Insights: Shotsy Appoints Eric Perakslis as Chief Science Officer

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source – businesswire